Benzinga | Jan 20, 2022 06:15AM EST

SVB Leerink Upgrades Calithera Biosciences to Outperform, Raises Price Target to $3

SVB Leerink analyst Jonathan Chang upgrades Calithera Biosciences (NASDAQ:CALA) from Market Perform to Outperform and raises the price target from $1 to $3.